Concord biotech Limited has fulfilled its quarterly regulatory obligations by submitting the required compliance certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The submission was made to both the National Stock Exchange of India Limited and BSE Limited on April 08, 2026.

Regulatory Compliance Details

The certificate was issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, which mandates quarterly reporting by listed companies regarding dematerialization activities. MUFG Intime India Private Limited, serving as the company's Registrar and Share Transfer Agent, issued the certificate dated April 03, 2026.

Certificate Confirmation

The certificate confirms that MUFG Intime India Private Limited did not receive any requests for dematerialization or rematerialization of equity shares during the quarter ended March 31, 2026. This confirmation is a mandatory requirement under Regulation 74(5) of the SEBI regulations.

Ashok Shetty, Sr. Vice President – Corporate Registry at MUFG Intime India Private Limited, signed the certificate on behalf of the registrar. The document was subsequently submitted by Paritosh Trivedi, Company Secretary and Compliance Officer of Concord Biotech Limited.

Stock Exchange Notification

Concord Biotech Limited formally notified both major Indian stock exchanges about this compliance submission:

• National Stock Exchange of India Limited (Symbol: CONCORDBIO)
• BSE Limited (Scrip Code: 543960)

The company requested both exchanges to take the certificate submission on record, completing the mandatory quarterly reporting process as required under SEBI regulations.

Company Information

Concord Biotech Limited, headquartered in Ahmedabad, Gujarat, maintains its registered office at B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway. The company operates under CIN No.: L24230GJ1984PLC007440 and continues to maintain compliance with all applicable regulatory requirements.

Concord Biotech Limited has successfully completed the acquisition of Celliimmune Biotech Private Limited for ₹66,00,000 on April 02, 2026. This strategic investment positions the company to advance pioneering research in DNA engineering for cancer therapeutics and develop innovative alternatives to conventional chemotherapy.

Acquisition Details

The acquisition involves 100% shareholding in Celliimmune Biotech Private Limited, making it a wholly owned subsidiary of Concord Biotech Limited. The transaction was completed through cash consideration and conducted on an arm's length basis.

Target Company Profile

Celliimmune Biotech Private Limited operates in the biopharmaceutical industry, specializing in the discovery, development, and commercialization of novel cell and gene therapy solutions. The company was incorporated under the Companies Act, 2013.

Strategic Objectives

The acquisition aligns with Concord Biotech's expansion into advanced therapeutic research. The primary objectives include:

• Advancing pioneering research in DNA engineering for cancer therapeutics
• Developing innovative alternatives to conventional chemotherapy
• Innovating new therapy for treatment of cancer
• Expanding capabilities in cell and gene therapy solutions

Related Party Transaction

The acquisition falls under the purview of Related Party Transaction as Celliimmune became a wholly owned subsidiary of Concord Biotech Limited. Prior to this acquisition, the promoter/promoter group held majority shareholding in the company, with Mr. Ankur Vaid and Ms. Sonal Kumra serving as directors of the company. The investment and subscription of shares was conducted at arm's length basis.

Regulatory Compliance

The company has made this disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. No governmental or regulatory approvals were required for this acquisition. The announcement follows the company's earlier intimation dated November 13, 2025.